摘要
目的分析血清CA125、HE4检测方法联合超声GI-RADS(影像报告数据系统)诊断方法在卵巢肿瘤方面的检测价值与诊断效能。方法研究对象选择2018年1月—2019年12月期间在该院接受治疗的90例卵巢肿瘤患者。所有患者在术前全部接受盆腔超声的检查,并且按照国际肿瘤分析简易标准展开GI-RADS分类,并按照血清肿瘤标记物人附睾蛋白4和糖类抗原125指标展开分类调整。1~3类判定为良性,4~5类判定为恶性。之后患者通过手术或超声引导穿刺活检获得病理结果,将其与检测结果展开对比。结果从卵巢肿块的穿刺活检结果来看,对应的分类结果符合率分别为100.0%、100.0%、97.8%、85.0%和100.0%,证实了在良性和恶性肿瘤的判定方面,血清CA125、HE4检测方法联合超声GI-RADS的准确率与超声引导穿刺活检的病理结果非常接近,可以在今后作为主要的判定依据。结论血清CA125、HE4检测方法联合超声GI-RADS在分类诊断卵巢肿瘤方面具有非常明确的作用,且可以尝试将其应用于不同形态的卵巢肿瘤诊断过程。
Objective To analyze the detection value and diagnostic efficacy of serum CA125 and HE4 detection methods combined with ultrasound GI-RADS(Image Reporting Data System)diagnostic methods in ovarian tumors.Methods The study subjects selected 90 patients with ovarian tumors who were treated in the hospital from January 2018 to December 2019.All patients were examined by pelvic ultrasound before surgery,and GI-RADS classification was carried out in accordance with the International Tumor Analysis Simple Standards,and classification and adjustment were carried out according to the serum tumor markers human epididymal protein 4 and carbohydrate antigen 125 indicators.Categories 1-3 were judged as benign,and categories 4-5 were judged as malignant.After that,the patient obtains the pathological results through surgery or ultrasound-guided needle biopsy,which was compared with the test results.Results Judging from the results of biopsy of ovarian masses,the corresponding classification results coincided with rates were 100.0%,100.0%,97.8%,85.0% and 100.0%,which confirmed that serum CA125,HE4 in the determination of benign and malignant tumors;the accuracy of the detection method combined with ultrasound GI-RADS was very close to the pathological results of ultrasound-guided needle biopsy,which can be used as the main basis for judgment in the future.Conclusion The detection method of serum CA125 and HE4 combined with ultrasound GI-RADS has a very clear role in the classification and diagnosis of ovarian tumors,and it can be tried to be applied to the diagnosis process of ovarian tumors of different forms.
作者
齐立中
QI Li-zhong(Department of Laboratory Medicine,Weifang Hospital of Traditional Chinese Medicine,Weifang,Shandong Province,261041 China)
出处
《世界复合医学》
2021年第3期44-46,共3页
World Journal of Complex Medicine
